---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061552"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:00:16.362226+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D

## Summary
- Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.
- PC14586 PYNNACLE: 38% ORR at 2000 mg RP2D (6/16 evaluable, TP53 Y220C/KRAS wild-type).
- Median duration of response 7 months across ovarian, breast, prostate, SCLC, endometrial cancers.
- Registrational Phase 2 trial to start Q1 2024; RP2D aligned with FDA in Q3 2023 meeting.
- Raised $35.1M net via ATM facility during 9mo; R&D expenses increased to $42.5M.

## SEC filing metadata
- accession: 0000950170-23-061552
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/0000950170-23-061552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/pmvp-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061552
- JSON: https://secwatch.observer/filing/0000950170-23-061552.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061552.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/0000950170-23-061552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.